(Q36508350)

14 August 2017

Effects of a single injection of teriparatide on bone turnover markers in postmenopausal women (English)

1 reference

14 August 2017

M Shiraki

1

1 reference

14 August 2017

T Sugimoto

series ordinal

2

1 reference

14 August 2017

T Nakamura

series ordinal

3

1 reference

14 August 2017

language of work or name

English

0 references

publication date

24 October 2012

1 reference

Osteoporosis International

14 August 2017

1 reference

14 August 2017

24

1 reference

14 August 2017

1

1 reference

14 August 2017

219-226

1 reference

https://scigraph.springernature.com/pub.10.1007/s00198-012-2159-7

14 August 2017

0 references

cites work

Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3536955

The use of parathyroid hormone in the treatment of osteoporosis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3536955

Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3536955

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3536955

Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3536955

Interpretation of serum calcium in patients with abnormal serum proteins.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3536955

Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration

21 September 2018

1 reference

12 December 2020

Comparison of the effects of intermittent and continuous administration of human parathyroid hormone(1-34) on rat bone

1 reference

12 December 2020

Effect of an intermittent weekly dose of human parathyroid hormone (1-34) on osteoporosis: a randomized double-masked prospective study using three dose levels

1 reference

12 December 2020

Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk

1 reference

12 December 2020

Changes in vitamin D metabolites during teriparatide treatment

1 reference

12 December 2020

Rapid and robust response of biochemical markers of bone formation to teriparatide therapy

1 reference

12 December 2020

Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment

1 reference

12 December 2020

Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis

1 reference

12 December 2020

Association of severe vertebral fractures with reduced quality of life: reduction in the incidence of severe vertebral fractures by teriparatide

1 reference

12 December 2020

Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial

1 reference

12 December 2020

10.1007/S00198-012-2159-7

Identifiers

DOI

1 reference

14 August 2017

1 reference

14 August 2017

1 reference